Business Context and Reporting Period
Shuttle Pharmaceuticals Holdings, Inc. filed its Form 10-K for the fiscal year ended December 31, 2022. The company is a clinical-stage pharmaceutical developer focused on radiation sensitizers and immune-regulating therapies for cancer. Its lead candidate, Ropidoxuridine, has completed a Phase I trial; its HDAC inhibitor candidates remain preclinical.
- Ropidoxuridine: planned Phase II development for glioblastoma and sarcoma; the company anticipated submitting an IND for glioblastoma in the second quarter of 2023.
- SP-2-225: preclinical selective HDAC6 inhibitor; IND-enabling work was planned for 2023, with a potential Phase I trial in 2024.
- The company had seven employees and no commercial products, sales, marketing, or distribution capabilities.
- The common stock began trading on Nasdaq under “SHPH” on August 29, 2022.
Financial Results and Key Metrics
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Net research and development expense | $1.489 million | $1.022 million | Up 46% |
| General and administrative expense | $0.199 million | $0.037 million | Up 445% |
| Legal and professional expense | $0.867 million | $0.685 million | Up 27% |
| Total operating expenses | $2.554 million | $1.743 million | Up 47% |
| Net loss | $3.028 million | $1.152 million | Up 163% |
| Net loss attributable to common stockholders | $3.099 million | $1.255 million | Up 147% |
| Basic and diluted loss per share | $0.29 loss | $0.12 loss | Higher loss |
| Cash used in operating activities | $2.710 million | $0.300 million | Higher use |
| Cash provided by financing activities | $10.623 million | $0.688 million | Up materially |
| Cash at year-end | $8.417 million | $0.505 million | Up $7.912 million |
There is no meaningful revenue-based margin because the company generated no revenue. Operating losses were driven primarily by research and development, legal and professional costs, and financing-related interest expense. Interest expense increased to $0.918 million, including debt discount amortization.
- Current assets were $8.578 million and current liabilities were $0.976 million at December 31, 2022.
- Working capital improved to $7.603 million from a $1.708 million deficit in 2021.
- Total assets were $8.654 million; stockholders’ equity was $7.678 million versus a $1.628 million deficit in 2021.
- Accumulated deficit was $8.895 million.
- No investing cash flows were reported in either year.
- Year-end debt included approximately $685,000 of related-party notes and $98,000 of accrued related-party interest; other notes payable and PPP obligations had been settled or forgiven by year-end.
Material Changes Versus the Prior Comparable Period
- R&D spending increased 46% to $1.489 million net of NIH reimbursements, while gross R&D costs increased to $1.700 million from $1.527 million. NIH reimbursements declined to $0.211 million from $0.505 million as the funded projects concluded.
- Operating expenses increased 47%, reflecting greater R&D activity, IPO preparation costs, public-company expenses, and higher professional fees.
- Net loss increased by $1.876 million, primarily because of higher operating expenses and $0.918 million of interest expense. The prior year benefited from a larger warrant-liability gain.
- The company completed its IPO and overallotment in September 2022. The filing reports aggregate gross IPO proceeds of approximately $11.454 million and net common-stock proceeds of approximately $10.022 million after issuance costs.
- Series A preferred stock converted into common stock and warrants upon the IPO; no preferred shares remained outstanding at year-end.
- The company eliminated its warrant liability by year-end and reported no derivative financial instruments at December 31, 2022.
- Management stated that the company had adequate funding after the IPO and subsequent financing activities, but additional funding will be required for later-stage clinical development.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected to use available capital to fund IND-enabling activities and Phase I and Phase II development, including Ropidoxuridine, IPdR/TPI, and the HDAC platform.
- Management believed existing resources would fund operations through 2024. This is an estimate and depends on development costs, financing conditions, and clinical progress.
- On January 11, 2023, the company issued a $4.3 million convertible note for $4.0 million of gross proceeds. The note bears 5% interest and amortizes over 26 months. Conversion pricing is based partly on future market prices, creating potential dilution.
- The related warrant covers 1,018,079 shares at $2.35 per share and could provide approximately $2.4 million of additional gross proceeds if exercised.
- On February 2, 2023, the company issued 50,998 shares upon conversion of $86,292 of principal and unpaid interest under the new note.
- The company paid approximately $625,000, including accrued interest, to retire two related-party notes on January 15, 2023.
- The company has no approved products and expects continuing losses and negative operating cash flow. It will require substantial additional capital, particularly for Phase III trials and commercialization.
- Key risks include clinical-trial failure or delay, FDA rejection or additional trial requirements, dependence on CROs and third-party manufacturers, limited operating history, patent challenges, reimbursement and pricing pressure, competition, dilution from equity or convertible debt, and stock-price volatility.
- The company relies on third-party manufacturers and has no owned manufacturing facilities or long-term supply agreements.
- Management identified weaknesses in internal control over financial reporting, including insufficient accounting personnel, documentation and file-management limitations, and an inadequate financial-statement close process. Remediation measures were underway.
- No material legal proceedings or material off-balance-sheet arrangements were reported.
Important Facts for Investors to Verify
- Verify the company’s cash runway against actual quarterly cash burn and the repayment and conversion terms of the Alto convertible note.
- Monitor submission and acceptance of the planned Ropidoxuridine IND, Phase II trial initiation, enrollment, safety results, and FDA feedback.
- Assess whether the company can obtain sufficient additional capital without substantial dilution or unfavorable debt terms.
- Reconcile reported IPO proceeds, issuance costs, outstanding shares, warrants, and potential dilution from the equity incentive plan and convertible securities.
- Review remediation of internal-control weaknesses and any subsequent auditor or SEC findings.
- Track the status of patent applications, orphan-drug designations, manufacturing milestones, and third-party supply arrangements.